Mereo BioPharma Group Stock (NASDAQ: MREO)

Mereo BioPharma Group

MEREO BIOPHARMA GROUP PL-ADR

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BWIN

MREO

This Roper Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday


Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable

Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential

ServiceNow

RCEL

This ServiceNow Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group PLC

Financing

Press Releases

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Earnings

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Abeona Therapeutics

Absci

Abivax

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

aTyr Pharma

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cidara Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

CytomX Therapeutics

Emergent BioSolutions

Erasca

Humacyte

ITeos Therapeutics

Myriad Genetics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Tourmaline Bio

Verve Therapeutics

Needham

JP Morgan

Cantor Fitzgerald

LifeSci Capital

Jefferies

Comments

Mereo BioPharma Group

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell